Profile data is unavailable for this security.
About the company
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
- Revenue in USD (TTM)15.50bn
- Net income in USD1.33bn
- Incorporated2016
- Employees89.00k
- LocationIQVIA Holdings Inc2400 ELLIS ROADDURHAM 27703United StatesUSA
- Phone+1 (919) 998-2000
- Fax+1 (302) 636-5454
- Websitehttps://ir.iqvia.com/
Mergers & acquisitions
| Acquired company | IQV:NYQ since announced | Transaction value |
|---|---|---|
| Shanghai Illuminera Digital Technology Co Ltd | -31.06% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Summit Therapeutics Inc | 0.00 | -240.76m | 18.57bn | 159.00 | -- | 53.84 | -- | -- | -0.3309 | -0.3309 | 0.00 | 0.4643 | 0.00 | -- | -- | 0.00 | -85.89 | -78.31 | -95.86 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Insmed Inc | 381.03m | -1.01bn | 18.63bn | 1.27k | -- | 180.10 | -- | 48.88 | -5.95 | -5.95 | 2.21 | 0.5451 | 0.2573 | 0.9753 | 8.98 | 299,787.60 | -68.42 | -44.83 | -88.04 | -51.79 | 76.49 | 77.08 | -265.93 | -226.78 | 5.44 | -31.80 | 0.9194 | -- | 19.17 | 21.66 | -21.91 | -- | -12.30 | -- |
| Iqvia Holdings Inc | 15.50bn | 1.33bn | 28.16bn | 89.00k | 22.18 | 4.74 | 11.48 | 1.82 | 7.34 | 7.34 | 85.31 | 34.33 | 0.5751 | -- | 4.63 | 176,102.30 | 4.97 | 4.03 | 6.65 | 5.17 | 34.72 | 34.47 | 8.64 | 7.28 | -- | 3.65 | 0.7054 | 0.00 | 2.81 | 6.80 | 1.10 | 48.36 | 0.678 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 19.03m | 10.81% |
| Harris Associates LPas of 31 Mar 2025 | 11.17m | 6.34% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 9.88m | 5.61% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 7.72m | 4.39% |
| GIC Pte Ltd. (Investment Management)as of 31 Mar 2025 | 6.54m | 3.72% |
| Canada Pension Plan Investment Boardas of 31 Mar 2025 | 4.59m | 2.61% |
| Geode Capital Management LLCas of 31 Mar 2025 | 4.24m | 2.41% |
| AllianceBernstein LPas of 31 Mar 2025 | 3.54m | 2.01% |
| Farallon Capital Management LLCas of 31 Mar 2025 | 3.41m | 1.94% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 2.13m | 1.21% |
